Acologix, Inc. Launches Second Phase II Clinical Study for AC-100 (Dentonin^®)

Hayward, CA – May 25, 2005 — Acologix, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase II study of AC-100 (Dentonin™) for the treatment of periodontal bone loss. AC-100 is delivered during periodontal surgery in combination with a collagen matrix to re-grow bone that has been lost due to periodontal disease. There are currently more than 2 million periodontal surgeries performed each year in the United States. Based on activities observed in preclinical studies, AC-100 is expected to enhance the healing of periodontal defects. This periodontal study, being conducted in Serbia-Montenegro, is the second Phase II clinical study of AC-100 launched by Acologix in 2005.

“AC-100 has potential as a very exciting new periodontal therapy that appears to work by inducing natural reparative mechanisms of both bone and dental cells consequently stimulating the rapid onset of bone healing and periodontal repair” said David L. Cochran, DDS, PhD University of Texas Health Sciences Center, San Antonio, TX. Dr. Cochran added, “Notably, AC-100 stimulates the biological events that take place during the natural development of the periodontal tissues and offers the potential to be a periodontal therapy that can simultaneously stimulate the regeneration of all the components of the periodontium — bone, cementum and ligaments, leading to a healthier and stronger tooth structure.”

“This is an exciting development for Acologix, with AC-100 in two separate Phase II studies for regeneration of dental and bone tissues, respectively. Given the drug’s unique and selective biological profile, we envision that next clinical development will target orthopedics,” said Yoshi Kumagai, President and CEO of Acologix, Inc.

AC-100 is a synthetic peptide derived from an endogenous human protein produced by bone and dental cells. In several preclinical models, AC-100 has demonstrated potent and selective dental tissue and bone formation activity. Acologix has completed a Phase I clinical study of AC-100 in healthy volunteers and was well tolerated. AC-100 is being developed for dental, periodontal and orthopedic applications.

About Acologix, Inc.

Acologix strives to improve patients’ lives by developing and commercializing innovative biopharmaceuticals targeting “osteo-renal” (bone and kidney) diseases. Acologix’s substantial expertise in the mineral metabolism sciences is the key to solving major osteo-renal health problems. Periodontal disease, general dentistry, oral care, orthopedics, chronic kidney failure, and renal osteodystrophy represent significant underserved medical needs. Acologix is unique in its focus on these rapidly growing health care problems.

This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix’s business.

Company Contact

Yoshi Kumagai
President and CEO
Phone: 510.512.7200
Fax: 510.786.1116